1 BTC
=
- USD
Mainz Biomed N.V. Ordinary Shares
As of June 19, 2026 at 23:43 UTC
Chart
About Mainz Biomed N.V. Ordinary Shares
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
MYNZ in Bitcoin terms
Mainz Biomed N.V. Ordinary Shares is tracked on Roxom Terminal for users who want to follow and trade global stocks in a Bitcoin-denominated market environment.
- Mainz Biomed N.V. Ordinary Shares is part of Roxom's global stock coverage.
- BTC-denominated charting frames stock performance against Bitcoin instead of fiat alone.
- The global terminal hub links individual stock pages into a crawlable BTC-native market map.
Market Statistics
Trading Metrics
How to Buy MYNZ
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy MYNZ
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe article discusses two small-cap biotech companies with high-risk, high-potential investment opportunities: Mainz Biomed and NanoViricides. Both companies are developing innovative medical technologies but face significant financial challenges and are pre-revenue.
Mainz Biomed conducted a feasibility study on a non-invasive blood test for early pancreatic cancer detection, achieving 100% sensitivity and 95% specificity in identifying cancer and precancerous lesions across a 30-subject cohort.
Mainz Biomed reported a 33% increase in lab network revenue, a 30% decrease in operating loss, and an 18% decrease in net loss in 2024. The company made progress with strategic partnerships and its next-generation colorectal cancer screening product.
Mainz Biomed, a molecular genetics diagnostic company, is committed to combating colorectal cancer (CRC) by advancing diagnostic solutions for early detection. The company's flagship product, ColoAlert, and its next-generation screening method, which combines mRNA biomarkers, the FIT test, and a proprietary AI algorithm, demonstrate high sensitivity and specificity for detecting advanced adenomas, highlighting the potential for early intervention and prevention.
Mainz Biomed, a molecular genetics diagnostic company, has partnered with labor team, a Swiss diagnostic laboratory, to introduce its DNA-based colorectal cancer screening test, ColoAlert, to the Swiss market. The partnership aims to increase participation in early detection and prevention of colorectal cancer in Switzerland.